AbbVie Acquires Landos Biopharma for $137.5 Million 

by | Mar 25, 2024 1:52 pm | Biotechnology

On March 25, Chicago-based AbbVie Inc. announced that it entered into an agreement to acquire Landos Biopharma for $137.5 million.  AbbVie will acquire Landos at a price of $20.42 per share in cash upon closing, plus one non-tradable contingent value right per share with a value of up to $11.14 per share, or approximately an additional $75 million in the aggregate, subject to the achievement of a clinical development milestone.  Landos Biopharma is a clinical stage biopharmaceutical company focused on the development of first-in-class oral therapeutics for patients with autoimmune diseases.  Landos’ lead investigational asset is NX-13, a first-in-class oral NLRX1... Read More »
TowerBrook & Ascension Acquire Hospice Compassus in $1 Billion Deal

TowerBrook & Ascension Acquire Hospice Compassus in $1 Billion Deal

by | Oct 7, 2019 2:04 pm | Home Health & Hospice, Hospitals, Private Equity

TowerBrook Capital Partners and Ascension have joined forces in a hospice deal worth $1 billion, or 11.8x revenue. The joint venture is buying Hospice Compassus, which provides hospice, palliative and home health care and services to patients in more than 25 states, from Formation Capital and Audax Private Equity. Towerbrook and Ascension will own equal stakes in Hospice Compassus after buying the hospice firm an auction that started in early 2019. Formation and Audax backed Hospice Compassus for roughly five years, recapitalizing the company in 2014 for roughly $300 million, according to the same report. Although it’s no surprise that PE firms are big players in the Home Health and... Read More »